Stay updated with breaking news from Her2 Neu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A review of over 300,000 patients with invasive breast cancer found that breast cancer receptor status testing was less likely to occur in elderly, rural, and Black women.
New data show that Black women with node positive HR+/HER2- breast cancer have worse outcomes than their white counterparts, although the difference was no longer significant after adjustment for BMI.
Zolbetuximab is an investigational first-in-class monoclonal antibody targeting Claudin 18.2 (CLDN18.2), for the first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
The agency has granted an accelerated approval for trastuzumab deruxtecan (Enhertu) to be used in patients with metastatic non–small cell lung cancer whose tumors have HER2 mutations.
Breast cancer patients with low levels of HER2 expression, previously considered untreatable with HER2-targeted therapies, had improved progression-free survival with trastuzumab deruxtecan (Enhertu).